Awiqli, the Once-Weekly Basal Insulin: Why It’s Interesting, What to Consider, and Why Support Still Matters
Awiqli, the first FDA-approved once-weekly basal insulin for adults with type 2 diabetes, could change how some people approach insulin therapy. Here’s what makes it interesting, the pros and cons to consider, and why support tools and care-team conversations still matter.
